AOD-9604 vs 5-Amino-1MQ
AOD-9604 is not FDA-approved and rated 3/5 for evidence; 5-Amino-1MQ is not FDA-approved and rated 2/5. AOD-9604 has more human evidence behind it. AOD-9604 is banned in sport by WADA; 5-Amino-1MQ is not. Both are used for metabolic & weight goals.
| Compare |  AOD-9604A growth-hormone fragment developed for obesity — it failed its key trial. |  5-Amino-1MQA small-molecule NNMT blocker with mouse data only — not actually a peptide. |
|---|---|---|
| Category | Metabolic & Weight | Metabolic & Weight |
| Evidence | 3/5Human trials exist and showed it was well tolerated, but the largest (phase 2b, 536 people) missed its weight-loss endpoint. Positive findings are mostly from animals. | 2/5Cell studies and a small number of mouse studies; no published human trials. |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Not prohibited |
| Also known as | Anti-Obesity Drug 9604, Tyr-hGH(177-191), hGH fragment 176-191 (modified) | 5-amino-1-methylquinolinium, NNMT inhibitor |
| How it works | Proposed to stimulate fat breakdown (lipolysis) and block fat storage in fat cells, mimicking a region of GH. It does not raise IGF-1 the way full GH does. Mechanism in humans is not well established. | Inhibits nicotinamide N-methyltransferase (NNMT). Less NNMT activity is thought to preserve NAD+ and SAM (a methyl donor) inside fat cells, nudging them to burn more energy and store less fat. This is based on cell and mouse work. |
| Half-life | Short (minutes to under an hour); not well characterized | Not established in humans |
| Commonly reported doses |
|
|
| Route | Subcutaneous, abdomen | Subcutaneous |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest price per mg | $6.00 (5 mg vial, 40% off) | $0.60 (50 mg vial, 40% off) |
| Latest lab purity | 99.68% (lot AOD0002) | 99.97% (lot AMQ0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.